The effect of interferon therapy on erythrocyte membrane Na+,K+ ATP activity in patients with chronic hepatitis B and C virus infections

Basit Öğe Kaydı
dc.contributor.authorKuralay, F
dc.contributor.authorTanyalcin, T
dc.contributor.authorKutay, F
dc.contributor.authorErsoz, G
dc.contributor.authorYuce, G
dc.contributor.authorBatur, Y
dc.date.accessioned2019-10-27T11:51:38Z
dc.date.available2019-10-27T11:51:38Z
dc.date.issued1998
dc.departmentEge Üniversitesien_US
dc.description.abstractIn order to evaluate the effect of alpha interferon on erythrocyte membrane Na-,K- ATPase (EC 3.6. 1.37) activity, 10 patients with chronic hepatitis B virus (HBV) infection and 8 patients with chronic hepatitis C virus (HCV) infection were investigated. Erythrocyte membrane Na+,K+ ATPase activity was determined in controls and in patients with HBV and HCV infection. Na+, K+ ATPase activity was significantly less in untreated patients with (HBV) infection (n = 20; 0.134 +/- 0.073 mu mol of phosphate produced per milligram of protein per hour) and (HCV) infection (n = 11; 0.44 +/- 0.049) when compared to the controls (n = 10; 0.219 +/- 0.055). Among these subjects patients were treated with interferon and following treatment, significant elevation of Na+, K+ ATPase activity was seen in patients with HCV (n = 8; 0.183 +/- 0.044; P = 0.049) and HBV (n = 10, 0.213 +/- 0.095, P = 0.0069) infections when compared with the pre-treatment values (n = 8; 0.152 +/- 0.050) and (n = 10, 0.131 +/- 0.083), respectively. Normalization of serum alanin amino transferase levels (ALT) at treatment cessation was seen in 8 of 10 (%80) HBV infected patients of whom 2 of 8 (%25) had sustained ALT responses within three months after the end of treatment. In HCV infected patients 1 of 8 (%12.5) had sustained response following treatment. At the end of treatment, although Na+, K+ ATPase was restored in both of the patients groups, relative changes in enzyme activity in relation to relative reduction in ALT levels as a response to IFN therapy were not correlated.en_US
dc.identifier.endpage1198en_US
dc.identifier.issn1039-9712
dc.identifier.issue6en_US
dc.identifier.pmid9762418en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1189en_US
dc.identifier.urihttps://hdl.handle.net/11454/34600
dc.identifier.volume45en_US
dc.identifier.wosWOS:000075831300014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Austen_US
dc.relation.ispartofBiochemistry and Molecular Biology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecterythrocyte membraneen_US
dc.subjectinterferon therapyen_US
dc.subjecthepatitis B virusen_US
dc.subjecthepatitis C virusen_US
dc.titleThe effect of interferon therapy on erythrocyte membrane Na+,K+ ATP activity in patients with chronic hepatitis B and C virus infectionsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu